Date Title Description PDF
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download
12 Apr 2021 On business and financial situation The Company releases the press release related to its participation in the manufacture of the active substance of Moderna’s COVID-19 vaccine. Download
02 Mar 2021 On business and financial situation The Company releases an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download

Pages

Date Title Description PDF
14 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 Download
07 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 28 February 2022 and 4 March 2022 Download
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download

Pages

Date Title Description PDF
04 Apr 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the first quarter of 2019 Download
19 Mar 2019 R&D: new licenses, patents and registered trademarks ROVI Announces Positive Topline Results from Phase 3 study of Doria® in Patients with Schizophrenia Download
26 Feb 2019 Informe Anual de Remuneraciones de los Consejeros ROVI releases the 2018 annual report regarding remuneration of the members of the Board of Directors  Download
26 Feb 2019 Informe Anual de Gobierno Corporativo ROVI releases the 2018 Annual Corporate Governance Report Download
26 Feb 2019 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages